Melanoma Clinical Trials in Pennsylvania

Showing 61-80 of 146 trials

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NCT03665285

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Advanced or Metastatic Solid TumorsLung CancerBreast Cancer+6 more

NextCure, Inc.109 participantsStarted Oct 2018

Los Angeles, California, United States • New Haven, Connecticut, United States • Hackensack, New Jersey, United States +3 more locations

TERMINATEDPHASE487 miles

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

NCT01856023

Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy. Treatment Arm 1: "HD IL-2 first, then ipilimumab" Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab. Treatment Arm 2: Ipilimumab first then HD IL-2 Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.

Metastatic Melanoma

Clinigen, Inc.29 participantsStarted May 2013

Tucson, Arizona, United States • La Jolla, California, United States • Miami Beach, Florida, United States +9 more locations

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Melanoma Trials in Other Cities

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Neoadjuvant and Adjuvant Checkpoint Blockade

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Other Conditions in Pennsylvania